2024 Rome, Italy

I-035 Rolien Bosch
From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model
Wednesday 10:20-11:50
III-069 Kristin C. Carlsson Petri
TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology
Thursday 09:50-11:20
IV-005 Chaozhuang Shen
A Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population
Thursday 15:00-16:30
IV-091 Jan-Georg Wojtyniak
Population Pharmacokinetics of Survodutide in Subjects with Overweight or Obesity with and without Type 2 Diabetes Mellitus Based on Phase I and Phase II Data
Thursday 15:00-16:30